Terms: = Head and neck cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Staging
26 results:
1. [Enhancing survival outcomes in stage Ⅲ gastric/esophagogastric junction cancer: a retrospective study of immune checkpoint inhibitors and adjuvant chemotherapy based on real-world data].
Yang XQ; Rao Z; Wei HK; Xue ZC; Liu HY; Duan QF; Sun XW; Wang W
Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Apr; 27(4):395-402. PubMed ID: 38644245
[No Abstract] [Full Text] [Related]
2. Neoadjuvant pd-1 Plus Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.
Qian T; Liu D; Cao G; Chen Z; Zhang Q
Technol Cancer Res Treat; 2024; 23():15330338241231610. PubMed ID: 38497137
[TBL] [Abstract] [Full Text] [Related]
3. Temporal bone management in external and middle ear carcinoma.
Gowrishankar S; Borsetto D; Marinelli J; Panizza B
Curr Opin Otolaryngol Head Neck Surg; 2024 Apr; 32(2):138-142. PubMed ID: 38193562
[TBL] [Abstract] [Full Text] [Related]
4. Modern diagnostics and treatment of Merkel cell carcinoma.
Weilandt J; Peitsch WK
J Dtsch Dermatol Ges; 2023 Dec; 21(12):1524-1546. PubMed ID: 37875785
[TBL] [Abstract] [Full Text] [Related]
5. Nomogram Based on Liver Function Test Indicators for Survival Prediction in Nasopharyngeal Carcinoma Patients Receiving pd-1 Inhibitor Therapy.
Liang L; Li Y; Hong Y; Ji T; Chen H; Lin Z
Curr Oncol; 2023 Jul; 30(8):7189-7202. PubMed ID: 37623002
[TBL] [Abstract] [Full Text] [Related]
6. Intensive cycles of neoadjuvant camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma: a single-arm, phase II trial.
Yang G; Su X; Huang Y; Luo G; Wang Z; Cai P; Zheng Y; Bei T; Huang M; Bai Y; He H; Xiang J; Cai M; Zhong J; Guo Q; Zhang X
J Transl Med; 2023 Jun; 21(1):411. PubMed ID: 37355621
[TBL] [Abstract] [Full Text] [Related]
7. [Efficacy and safety of neoadjuvant chemotherapy combined with pd-1 antibody for esophageal squamous cell carcinoma in the real world].
Wu PY; Wang T; Chen BJ; Shi MK; Huang B; Wu ND; Qi L; Chang XF; Wang LF; Liu BR; Ren W
Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):170-174. PubMed ID: 36781239
[No Abstract] [Full Text] [Related]
8. The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma.
Lv H; Huang C; Li J; Zhang F; Gai C; Liu Z; Xu S; Wang M; Li Z; Tian Z
Front Immunol; 2022; 13():1100750. PubMed ID: 36741358
[TBL] [Abstract] [Full Text] [Related]
9. Nomogram Based on Monocyte-to-Lymphocyte Ratio to Predict Survival of Unresectable Esophageal Squamous Cell Carcinoma Who Receive First-Line pd-1/PD-L1 Inhibitors Combined with Chemotherapy.
Ma X; Ding Y; Qian J; Wan M; Li N; Mao C; Xiao C; Jiang H; Zheng Y; Wu L; Chen X; Xu N
Curr Oncol; 2022 Nov; 29(11):8937-8954. PubMed ID: 36421355
[TBL] [Abstract] [Full Text] [Related]
10. Impact of the combination of sintilimab and chemotherapy on the tumor and paratumor PD-L1, IDO, TIM-3, FOXP3+ and CD8 expressions in patients with advanced esophageal squamous cell carcinoma.
Zhang S; Cai H; Huang J; Wang G
Thorac Cancer; 2022 Dec; 13(23):3284-3294. PubMed ID: 36288460
[TBL] [Abstract] [Full Text] [Related]
11. American head and neck Society position statement on the use of pd-1 inhibitors for treatment of advanced cutaneous squamous cell carcinoma.
Schmalbach CE; Ow TJ; Choi KY; O'Leary M; Lin A; Hughley BB; Emerick KS; Moore B; Lee NY; Zandberg DP; Wang SJ
Head Neck; 2023 Jan; 45(1):32-41. PubMed ID: 36181317
[TBL] [Abstract] [Full Text] [Related]
12. Expression Profiles and Prognostic Value of Multiple Inhibitory Checkpoints in head and neck Lymphoepithelioma-Like Carcinoma.
Zou WQ; Luo WJ; Feng YF; Liu F; Liang SB; Fang XL; Liang YL; Liu N; Wang YQ; Mao YP
Front Immunol; 2022; 13():818411. PubMed ID: 35140722
[TBL] [Abstract] [Full Text] [Related]
13. Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial.
Schoenfeld JD; Hanna GJ; Jo VY; Rawal B; Chen YH; Catalano PS; Lako A; Ciantra Z; Weirather JL; Criscitiello S; Luoma A; Chau N; Lorch J; Kass JI; Annino D; Goguen L; Desai A; Ross B; Shah HJ; Jacene HA; Margalit DN; Tishler RB; Wucherpfennig KW; Rodig SJ; Uppaluri R; Haddad RI
JAMA Oncol; 2020 Oct; 6(10):1563-1570. PubMed ID: 32852531
[TBL] [Abstract] [Full Text] [Related]
14. Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced head and neck Squamous Cell Carcinoma: A Phase IB Study.
Powell SF; Gold KA; Gitau MM; Sumey CJ; Lohr MM; McGraw SC; Nowak RK; Jensen AW; Blanchard MJ; Fischer CD; Bykowski J; Ellison CA; Black LJ; Thompson PA; Callejas-Valera JL; Lee JH; Cohen EEW; Spanos WC
J Clin Oncol; 2020 Jul; 38(21):2427-2437. PubMed ID: 32479189
[TBL] [Abstract] [Full Text] [Related]
15. The Great Debate at "Melanoma Bridge", Naples, December 7th, 2019.
Ascierto PA; Agarwala SS; Eggermont A; Gershenwald JE; Grob JJ; Hamid O; Michielin O; Postow M; Puzanov I; Zarour HM; Caracò C; Testori A
J Transl Med; 2020 Apr; 18(1):171. PubMed ID: 32299446
[TBL] [Abstract] [Full Text] [Related]
16. Patterns of distant metastases in 215 Merkel cell carcinoma patients: Implications for prognosis and surveillance.
Lewis CW; Qazi J; Hippe DS; Lachance K; Thomas H; Cook MM; Juhlin I; Singh N; Thuesmunn Z; Takagishi SR; McEvoy A; Doolittle-Amieva C; Bhatia S; Paulson KG; O'Malley RB; Wang CL; Nghiem P
Cancer Med; 2020 Feb; 9(4):1374-1382. PubMed ID: 31883234
[TBL] [Abstract] [Full Text] [Related]
17. Association Between Programmed Death-Ligand 1 Expression and Clinicopathological Characteristics, Structural Recurrence, and Biochemical Recurrence/Persistent Disease in Medullary Thyroid Carcinoma.
Shi X; Yu PC; Lei BW; Li CW; Zhang Y; Tan LC; Shi RL; Wang J; Ma B; Xu WB; Wang X; Hu JQ; Huang NS; Wei WJ; Wang Y; Chen TZ; Wang YL; Ji QH
Thyroid; 2019 Sep; 29(9):1269-1278. PubMed ID: 31328653
[No Abstract] [Full Text] [Related]
18. A nomogram-based immunoprofile predicts overall survival for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy.
Duan J; Xie Y; Qu L; Wang L; Zhou S; Wang Y; Fan Z; Yang S; Jiao S
J Immunother Cancer; 2018 Oct; 6(1):100. PubMed ID: 30285868
[TBL] [Abstract] [Full Text] [Related]
19. Integrated genomic characterization of oral carcinomas in post-hematopoietic stem cell transplantation survivors.
Hanna GJ; Kofman ER; Shazib MA; Woo SB; Reardon B; Treister NS; Haddad RI; Cutler CS; Antin JH; Van Allen EM; Uppaluri R; Soiffer RJ
Oral Oncol; 2018 Jun; 81():1-9. PubMed ID: 29884406
[TBL] [Abstract] [Full Text] [Related]
20. Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-pd-1 immunotherapy.
Finazzi T; Rordorf T; Ikenberg K; Huber GF; Guckenberger M; Garcia Schueler HI
BMC Cancer; 2018 Apr; 18(1):395. PubMed ID: 29625593
[TBL] [Abstract] [Full Text] [Related]
[Next]
